The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?

MLA

Vegivinti, Charan Thej Reddy, et al. “The Role of Immune Checkpoint Inhibitors for Patients with Advanced Stage Microsatellite Stable Colorectal Cancer and High Tumor Mutation Burden: Quantity or Quality?” Expert Opinion on Biological Therapy, vol. 23, no. 7, July 2023, pp. 595–601. EBSCOhost, https://doi.org/10.1080/14712598.2023.2226327.

APA

Vegivinti, C. T. R., Gonzales Gomez, C., Syed, M., Ferrell, M., Cheng, S., Singhi, A., Saeed, A., & Sahin, I. H. (2023). The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality? Expert Opinion on Biological Therapy, 23(7), 595–601. https://doi.org/10.1080/14712598.2023.2226327

Chicago

Vegivinti, Charan Thej Reddy, Cyndi Gonzales Gomez, Masood Syed, Morgan Ferrell, Svea Cheng, Aatur Singhi, Anwaar Saeed, and Ibrahim Halil Sahin. 2023. “The Role of Immune Checkpoint Inhibitors for Patients with Advanced Stage Microsatellite Stable Colorectal Cancer and High Tumor Mutation Burden: Quantity or Quality?” Expert Opinion on Biological Therapy 23 (7): 595–601. doi:10.1080/14712598.2023.2226327.